N-tert-Butyl-3-oxo-4-aza-5alpha-androsta-1-ene-17-carboxamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: N-tert-Butyl-3-oxo-4-aza-5alpha-androsta-1-ene-17-carboxamide
• 英文别名: (3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
• 化学式: C₂₃H₃₆N₂O₂
• 分子量: 372.5
• InChiKey: DBEPLOCGEIEOCV-NAYRGPGOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• HIGH THROUGHPUT METHODS, PROTEIN INHIBITORS, AND USES THEREOF
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20200140500A1

  公开（公告）日：2020-05-07

  The invention provides high throughput methods, protein inhibitors, and uses thereof. The invention provides high throughput methods of screening compounds for modulation of protein thermal stability, the method comprising contacting a protein with each of a plurality of test compounds; and (b) measuring the melting transition (T m ) of the protein in the presence of each of the plurality of test compounds, wherein a compound that decreases or increases the apparent Tm by at least 2 standard deviations is identified as a pharmacological protein chaperone.
• COMPOUNDS AND PRODRUGS THEREOF FOR THE TREATMENT OF OPHTHALMIC DISEASE
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20200138832A1

  公开（公告）日：2020-05-07

  The invention provides inhibitors of α-crystallin aggregation, including prodrugs of a steroid and/or sterol, and methods of using said α-crystallin aggregation inhibitors to, e.g., treat or prevent cataracts in a subject having or at risk of developing cataracts.